# An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)

> **NCT02529930** · PHASE1,PHASE2 · COMPLETED · sponsor: **Nykode Therapeutics ASA** · enrollment: 34 (actual)

## Conditions studied

- High Grade Cervical Intraepithelial Neoplasia

## Interventions

- **BIOLOGICAL:** VB10.16 Immunotherapy (DNA vaccine)

## Key facts

- **NCT ID:** NCT02529930
- **Lead sponsor:** Nykode Therapeutics ASA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2019-01-31
- **Final completion:** 2019-01-31
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2022-07-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02529930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02529930, "An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02529930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*